NASDAQ:SNTI Senti Biosciences (SNTI) Stock Forecast, Price & News $1.00 -0.01 (-0.99%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$0.99▼$1.0350-Day Range$0.88▼$1.1452-Week Range$0.86▼$8.77Volume16,792 shsAverage Volume39,914 shsMarket Capitalization$44.17 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Senti Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside350.0% Upside$4.50 Price TargetShort InterestBearish2.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.54) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 starsMedical Sector641st out of 987 stocksBiological Products, Except Diagnostic Industry105th out of 160 stocks 3.3 Analyst's Opinion Consensus RatingSenti Biosciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.50, Senti Biosciences has a forecasted upside of 350.0% from its current price of $1.00.Amount of Analyst CoverageSenti Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.01% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Senti Biosciences has recently increased by 2.86%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSenti Biosciences does not currently pay a dividend.Dividend GrowthSenti Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNTI. Previous Next 1.7 News and Social Media Coverage News SentimentSenti Biosciences has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Senti Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for SNTI on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Senti Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Senti Biosciences is held by insiders.Percentage Held by Institutions40.81% of the stock of Senti Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Senti Biosciences are expected to grow in the coming year, from ($1.54) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Senti Biosciences is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Senti Biosciences is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSenti Biosciences has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Senti Biosciences (NASDAQ:SNTI) StockSenti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More Receive SNTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SNTI Stock News HeadlinesJune 10, 2023 | americanbankingnews.comContrasting Senti Biosciences (SNTI) & The CompetitionJune 5, 2023 | finance.yahoo.comHere's Why Senti Biosciences (NASDAQ:SNTI) Must Use Its Cash WiselyJune 10, 2023 | Vantage Point (Ad)Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. June 4, 2023 | americanbankingnews.comHead-To-Head Comparison: Seagen (NASDAQ:SGEN) versus Senti Biosciences (NASDAQ:SNTI)May 25, 2023 | americanbankingnews.comCritical Survey: Senti Biosciences (SNTI) and The CompetitionMay 24, 2023 | americanbankingnews.comSenti Biosciences (SNTI) & Its Rivals Financial ReviewMay 11, 2023 | msn.comChardan Capital Maintains Senti Biosciences (SNTI) Buy RecommendationMay 9, 2023 | finance.yahoo.comSenti Bio Announces First Quarter 2023 Results and Pipeline UpdatesJune 10, 2023 | Vantage Point (Ad)Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. May 2, 2023 | finance.yahoo.comSenti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual MeetingApril 17, 2023 | finance.yahoo.comSenti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR MeetingApril 14, 2023 | finance.yahoo.comSenti Bio to Participate in Upcoming Investor ConferencesMarch 25, 2023 | americanbankingnews.comSenti Biosciences (NASDAQ:SNTI) PT Lowered to $2.00March 24, 2023 | markets.businessinsider.comExpert Ratings for Senti BiosciencesMarch 24, 2023 | markets.businessinsider.comMorgan Stanley Reaffirms Their Hold Rating on Senti Biosciences (SNTI)March 24, 2023 | americanbankingnews.comSenti Biosciences (NASDAQ:SNTI) Price Target Lowered to $7.00 at Chardan CapitalMarch 24, 2023 | benzinga.comSenti Biosciences Stock (NASDAQ:SNTI), DividendsMarch 23, 2023 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent HighlightsMarch 22, 2023 | finance.yahoo.comSenti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent HighlightsMarch 14, 2023 | finance.yahoo.comSenti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR MeetingFebruary 6, 2023 | finance.yahoo.comInvestors in Senti Biosciences (NASDAQ:SNTI) have unfortunately lost 82% over the last yearFebruary 1, 2023 | finance.yahoo.comSenti Bio to Present at the SVB Securities Global Biopharma ConferenceJanuary 30, 2023 | msn.comChardan Capital Maintains Buy Rating for Senti Biosciences: Here's What You Need To KnowJanuary 27, 2023 | marketwatch.comSenti Biosciences Launches New Strategic Plan, Sees Cash Runway to 1Q 2024January 27, 2023 | finance.yahoo.comSenti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway GuidanceDecember 27, 2022 | finance.yahoo.comWe Think Senti Biosciences (NASDAQ:SNTI) Needs To Drive Business Growth CarefullyDecember 19, 2022 | finance.yahoo.comSenti Bio to Present at 41st Annual J.P. Morgan Healthcare ConferenceSee More Headlines SNTI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNTI Company Calendar Last Earnings3/22/2023Today6/10/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNTI CUSIPN/A CIK1854270 Webwww.sentibio.com Phone650-239-2030FaxN/AEmployees122Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.50 High Stock Price Forecast$7.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+350.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,210,000.00 Net Margins-1,457.24% Pretax Margin-1,457.24% Return on Equity-48.76% Return on Assets-35.49% Debt Debt-to-Equity RatioN/A Current Ratio6.26 Quick Ratio6.26 Sales & Book Value Annual Sales$4.29 million Price / Sales10.30 Cash FlowN/A Price / Cash FlowN/A Book Value$2.90 per share Price / Book0.34Miscellaneous Outstanding Shares44,170,000Free Float40,590,000Market Cap$44.17 million OptionableNot Optionable Beta2.48 Key ExecutivesDr. Timothy K. Lu M.D. (Age 42)Ph.D., Co-founder, CEO, Pres & Director Comp: $811.26kDr. James J. Collins Ph.D. (Age 57)Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director Comp: $41.49kDr. Deborah A. Knobelman Ph.D. (Age 49)CFO, Head of Corp. Devel. & Treasurer Comp: $600.22kMs. Susan D. Berland (Age 68)Sr. Financial Exec. & Independent Director Comp: $54.23kDr. Kanya Rajangam M.D. (Age 49)Ph.D., Head of R&D and Chief Medical Officer Comp: $679.71kDr. Philip Lee Ph.D. (Age 41)Co-Founder & CTO Dr. Wilson Wong Ph.D.Scientific Co-Founder & Member of Scientific Advisory BoardSusan KahlertControllerMore ExecutivesKey CompetitorsSynlogicNASDAQ:SYBXAchilles TherapeuticsNASDAQ:ACHLAvalo TherapeuticsNASDAQ:AVTXSoleno TherapeuticsNASDAQ:SLNOMinerva NeurosciencesNASDAQ:NERVView All CompetitorsInstitutional OwnershipPrice T Rowe Associates Inc. MDSold 86,151 shares on 5/15/2023Ownership: 7.852%Triatomic Management LPBought 59,208 shares on 5/3/2023Ownership: 0.477%ARK Investment Management LLCSold 24,360 shares on 4/17/2023Ownership: 4.305%View All Institutional Transactions SNTI Stock - Frequently Asked Questions Should I buy or sell Senti Biosciences stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNTI shares. View SNTI analyst ratings or view top-rated stocks. What is Senti Biosciences' stock price forecast for 2023? 4 brokerages have issued 1 year price targets for Senti Biosciences' stock. Their SNTI share price forecasts range from $2.00 to $7.00. On average, they anticipate the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 350.0% from the stock's current price. View analysts price targets for SNTI or view top-rated stocks among Wall Street analysts. How have SNTI shares performed in 2023? Senti Biosciences' stock was trading at $1.41 on January 1st, 2023. Since then, SNTI shares have decreased by 29.1% and is now trading at $1.00. View the best growth stocks for 2023 here. When is Senti Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our SNTI earnings forecast. How were Senti Biosciences' earnings last quarter? Senti Biosciences, Inc. (NASDAQ:SNTI) announced its earnings results on Wednesday, March, 22nd. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.05. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $1.92 million. Senti Biosciences had a negative trailing twelve-month return on equity of 48.76% and a negative net margin of 1,457.24%. What ETFs hold Senti Biosciences' stock? ETFs with the largest weight of Senti Biosciences (NASDAQ:SNTI) stock in their portfolio include ARK Genomic Revolution ETF (ARKG). What is Senti Biosciences' stock symbol? Senti Biosciences trades on the NASDAQ under the ticker symbol "SNTI." Who are Senti Biosciences' major shareholders? Senti Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.85%), ARK Investment Management LLC (4.31%) and Triatomic Management LP (0.48%). View institutional ownership trends. How do I buy shares of Senti Biosciences? Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Senti Biosciences' stock price today? One share of SNTI stock can currently be purchased for approximately $1.00. How much money does Senti Biosciences make? Senti Biosciences (NASDAQ:SNTI) has a market capitalization of $44.17 million and generates $4.29 million in revenue each year. The company earns $-58,210,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. How many employees does Senti Biosciences have? The company employs 122 workers across the globe. How can I contact Senti Biosciences? Senti Biosciences' mailing address is 2875 EL CAMINO REAL, REDWOOD CITY CA, 94061. The official website for the company is www.sentibio.com. The company can be reached via phone at 650-239-2030 or via email at irbd@dspc.bio. This page (NASDAQ:SNTI) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.